Latest Tyrosine kinase inhibitors Stories
New Studies Identify Molecular Target, Mitochondria-Specific Effects of ME-344; Results from First-in-Human Clinical Study Published in Cancer SAN DIEGO, May 4, 2015 /PRNewswire/ --
AUSTIN, Texas, March 12, 2015 /PRNewswire/ -- XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S.
NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company that develops and markets treatments for cancer.
RnRMarketResearch.com adds “Nintedanib (Colorectal Cancer) – Forecast and Market Analysis to 2023” to its store.
MTD Confirmed in Combination with Topotecan, First Patient Dosed in Cohort Expansion SAN DIEGO, Oct. 29, 2014 /PRNewswire/ -- MEI Pharma, Inc.
NEW YORK, July 17, 2014 /PRNewswire/ -- Exelixis, Inc. (Nasdaq: EXEL) is a development stage biotech company.
ROCKVILLE, Md., May 15, 2014 /PRNewswire/ -- EntreMed, Inc.
SOUTH SAN FRANCISCO, Calif., Feb.
- To befool; deceive; balk; jilt.
- An illusion; a trick; a cheat.